Skip to main content

Table 2 Inhibition (IC50) of HCT116 and MCF-7 cell lines and inhibition of Aurora-A kinase by compounds P (1–21)

From: Design, synthesis, anticancer evaluation and docking studies of novel 2-(1-isonicotinoyl-3-phenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one derivatives as Aurora-A kinase inhibitors

Comp IC50 ± SD (µM)
HCT-116a MCF-7a Aurora- Ab
P-1 2.30 ± 0.14 4.40 ± 0.18 2.34 ± 0.36
P-2 3.52 ± 0.33 3.26 ± 0.31 3.57 ± 0.35
P-3 4.47 ± 0.45 4.49 ± 0.42 7.25 ± 0.80
P-4 1.35 ± 0.07 2.55 ± 0.07 1.33 ± 0.15
P-5 3.88 ± 0.16 4.01 ± 0.10 4.79 ± 0.83
P-6 0.37 ± 0.15 0.44 ± 0.06 0.18 ± 0.05
P-7 0.62 ± 0.03 0.88 ± 0.03 0.42 ± 0.12
P-8 5.35 ± 0.27 6.08 ± 0.24 7.32 ± 0.69
P-9 1.45 ± 0.18 1.62 ± 0.05 1.45 ± 0.05
P-10 0.78 ± 0.04 1.03 ± 0.11 0.65 ± 0.09
P-11 2.54 ± 0.20 2.53 ± 0.19 2.78 ± 0.14
P-12 4.06 ± 0.38 4.35 ± 0.47 5.59 ± 0.37
P-13 5.87 ± 0.42 8.21 ± 0.35 12.37 ± 0.85
P-14 4.08 ± 0.31 5.30 ± 0.62 5.52 ± 0.55
P-15 2.18 ± 0.15 2.34 ± 0.27 2.10 ± 0.13
P-16 2.01 ± 0.11 2.25 ± 0.25 2.10 ± 0.15
P-17 2.92 ± 0.26 3.24 ± 0.13 3.04 ± 0.48
P-18 1.52 ± 0.09 1.77 ± 0.15 1.62 ± 0.11
P-19 1.02 ± 0.12 1.21 ± 0.05 0.79 ± 0.07
P-20 0.42 ± 0.08 0.56 ± 0.06 0.22 ± 0.08
P-21 0.97 ± 0.10 1.10 ± 0.08 0.79 ± 0.07
VX-680 (Tozasertib) 0.30 ± 0.03 0.38 ± 0.02 0.13 ± 0.01
  1. aInhibition of growth of tumor cell lines
  2. bInhibition of Aurora-A kinase